RNA — Avidity Biosciences Cashflow Statement
0.000.00%
- $3.71bn
- $2.21bn
- $10.90m
- 49
- 11
- 39
- 24
Annual cashflow statement for Avidity Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -44.4 | -118 | -174 | -212 | -322 |
Depreciation | |||||
Non-Cash Items | 4.82 | 17.7 | 27.5 | 29.9 | 33.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.04 | 4.88 | 8.83 | 61.1 | -14.6 |
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -37.1 | -94.8 | -136 | -119 | -301 |
Capital Expenditures | -1.09 | -3.74 | -2.82 | -4.23 | -7.07 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -6.69 | -78.8 | -187 | -126 | -847 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -7.79 | -82.5 | -190 | -130 | -854 |
Financing Cash Flow Items | -24 | -11.3 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 272 | 176 | 346 | 93.9 | 1,192 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 227 | -1.01 | 19.9 | -155 | 37.3 |